Mdxhealth Sa (MXDHF) 5.7400 $MXDHF
MDxHealth Named Euronext Best BEL Small Company Performer for 2014
GlobeNewswire - Wed Jan 21, 1:05AM CST
MDxHealth SA (Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that Euronext granted the 2014 Best BEL Small Company Award, for the highest return among its peers, to MDxHealth. The award was presented to Dr. Jan Groen, CEO of MDxHealth, by M. Pieter De Crem, Secretary of State for Foreign Trade, at a ceremony last night at the Palais de la Bourse in Brussels, Belgium.
MDxHealth Licenses Epigenetic Technology to oncgnostics GmbH for Cervical Cancer Test
GlobeNewswire - Wed Jan 14, 1:06AM CST
MDxHealth SA (Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that it has granted a limited worldwide license for its patented methylation specific PCR (MSP) technology to oncgnostics GmbH in Jena, Germany.
MDxHealth CEO Dr Jan Groen to Deliver Keynote Presentation at Biomarkers from Research to Clinic Conference
GlobeNewswire - Mon Jan 05, 1:04AM CST
MDxHealth SA (Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, announced today that its CEO, Dr Jan Groen, will deliver a keynote presentation at the Biomarkers from Research to Clinic, Prognostic, Predictive & Point-of-Care Conference at 13:15 PST on January 15 in San Diego, CA, USA.
Exact Sciences: Caught Between Bulls And Bears
SNJBiostoxx - at Seeking Alpha - Tue Nov 18, 2:38AM CST
VIVO: 19.15 (+0.16), TMO: 127.61 (+0.78), EXAS: 25.56 (-0.54)
MDxHealth to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum
GlobeNewswire - Wed Nov 12, 2:35AM CST
MDxHealth SA (Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that CEO, Dr. Jan Groen, will present at the Canaccord Genuity Medical Technology & Diagnostics Forum, which is being held on November 20, 2014, at Westin Grand Central in New York. Dr. Jan Groen will make the Company's presentation at 1:30 PM Eastern Daylight Time. The presentation will be posted under the investor tab of the MDxHealth website (http://mdxhealth.com/investors/shareholder-information) after the conference.
MDXHealth - Piggybacking On Exact Sciences' Cologuard Success
SNJBiostoxx - at Seeking Alpha - Thu Nov 06, 10:43AM CST
EXAS: 25.56 (-0.54)
MDxHealth Provides Third Quarter 2014 Business Update
GlobeNewswire - Tue Nov 04, 1:08AM CST
MDxHealth SA (Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today provided its third quarter Business Update for the period ended September 30, 2014.
MDxHealth's ConfirmMDx Genes Identify Prostate Cancer Aggressiveness in Diagnostic Biopsies
GlobeNewswire - Fri Oct 10, 1:11AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced positive data from an important study confirming the ability of the ConfirmMDx genes to identify prostate cancer (PCa) aggressiveness in diagnostic biopsies. The data, presented at the European Association of Urology, Section Urological Research (ESUR) meeting in Glasgow, UK (October 9-11, 2014), confirmed that the epigenetic profile of ConfirmMDx genes generated by the test is strongly correlated with established risk stratification metrics, such as Gleason Score (GS) and the NCCN (National Comprehensive Cancer Network) risk categories.
MDxHealth Presents Results from Epigenetic Test to Identify Prostate Cancer Aggressiveness at the European Association of Urology Meeting 2014
GlobeNewswire - Tue Oct 07, 1:09AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the company will present results from a validation study of an epigenetic test to predict prostate cancer (PCa) aggressiveness at the European Association of Urology, Section Urological Research meeting in Glasgow, UK (October 9-11, 2014).
MDxHealth's ConfirmMDx for Prostate Cancer Test Qualifies for Medicare Coverage Effective November 3, 2014
GlobeNewswire - Tue Sep 23, 1:19AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that its ConfirmMDx for Prostate Cancer test qualifies for Medicare coverage effective November 3, 2014.
MDxHealth to Participate in the Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Mon Sep 08, 9:33AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the company will participate in the Rodman & Renshaw 16th Annual Global Investment Conference in New York, NY.
MDxHealth Reports First Half Year 2014 Results
GlobeNewswire - Thu Aug 21, 1:12AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced results of the first-half year ended June 30, 2014.
MDxHealth ConfirmMDx Biomarker Associated with the Risk of Recurrence for Early Stage Prostate Cancer Patients
GlobeNewswire - Mon Aug 18, 1:07AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that one of the ConfirmMDx for Prostate Cancer epigenetic genes is independently associated with risk of recurrence in patients with early prostate cancer (PCa). The results from this study, published in The Journal of Urology [The Journal of Urology (2014), doi: 10.1016/j.juro.2014.04.082], suggest that epigenetic analysis could play a clinical role in identifying patients who have a slow growing cancer eligible for active surveillance from those with a higher risk of recurrence who may benefit from a more aggressive therapeutic approach.
MDxHealth Signs Two New Insurance Agreements Providing Increased Access to ConfirmMDx for Prostate Cancer
GlobeNewswire - Thu Aug 14, 1:07AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that it has signed agreements with Ancillary Care Services (ACS), a subsidiary of American CareSource Holdings Inc. and separately, Consilium, LLC. ACS offers its providers quality and cost-effective healthcare services through their managed care network agreements covering 4.5 million lives. Consilium is a complete solution provider for out-of-network healthcare claims. The agreements provide patients access to MDxHealth's ConfirmMDx for Prostate Cancer test.
ANCI: 3.10 (-0.20)
MDxHealth (R) : MDxHealth Licensee Exact Sciences Receives FDA Approval for its Cologuard Colon Cancer Screening Assay
GlobeNewswire - Tue Aug 12, 2:05AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the U.S. Food and Drug Administration's (FDA) has approved Exact Sciences' Cologuard(R) stool-DNA-based, non-invasive colorectal cancer screening test. The test incorporates one of MDxHealth's epigenetic biomarkers, which was licensed to Exact Sciences in July 2010. Upon product launch, anticipated before the end of 2014, MDxHealth expects to receive milestone payments and royalties from the sale of the test under the terms of its licensing agreement.
ConfirmMDx Studies Highlighted by Elsevier, Publisher of The Journal of Urology(r)
GlobeNewswire - Tue Jul 22, 1:08AM CDT
Underscores Importance of Recent Confirmatory Clinical Validation Results Leading to Medicare Reimbursement Milestone
MDxHealth and Miraca Life Sciences Announce Agreement to Promote ConfirmMDx for Prostate Cancer
GlobeNewswire - Wed Jul 02, 1:06AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that it has entered into an agreement with Miraca Life Sciences (MLS), the nation's largest independent anatomic pathology lab, to promote MDxHealth's ConfirmMDx for Prostate Cancer test. Serving more than 5,500 patients each day, Miraca Life Sciences is a national leader in providing academic-caliber pathology services in the fields of dermatology, hematology, gastroenterology and urology.
MDxHealth Reports Fourth Quarter and Fiscal Year 2013 Results
GlobeNewswire - Thu Feb 27, 1:05AM CST
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced results for the fourth quarter and the fiscal year ended December 31, 2013. This year the company has changed its reporting currency to U.S. Dollars, while keeping its functional currency in Euros.
BAS: 7.28 (+0.62)
MDxHealth Named Euronext Best BEL Small Company Performer for 2014
GlobeNewswire - Wed Jan 21, 1:05AM CST
MDxHealth SA (Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that Euronext granted the 2014 Best BEL Small Company Award, for the highest return among its peers, to MDxHealth. The award was presented to Dr. Jan Groen, CEO of MDxHealth, by M. Pieter De Crem, Secretary of State for Foreign Trade, at a ceremony last night at the Palais de la Bourse in Brussels, Belgium.
MDxHealth Licenses Epigenetic Technology to oncgnostics GmbH for Cervical Cancer Test
GlobeNewswire - Wed Jan 14, 1:06AM CST
MDxHealth SA (Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that it has granted a limited worldwide license for its patented methylation specific PCR (MSP) technology to oncgnostics GmbH in Jena, Germany.
MDxHealth CEO Dr Jan Groen to Deliver Keynote Presentation at Biomarkers from Research to Clinic Conference
GlobeNewswire - Mon Jan 05, 1:04AM CST
MDxHealth SA (Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, announced today that its CEO, Dr Jan Groen, will deliver a keynote presentation at the Biomarkers from Research to Clinic, Prognostic, Predictive & Point-of-Care Conference at 13:15 PST on January 15 in San Diego, CA, USA.
Exact Sciences: Caught Between Bulls And Bears
SNJBiostoxx - at Seeking Alpha - Tue Nov 18, 2:38AM CST
VIVO: 19.15 (+0.16), TMO: 127.61 (+0.78), EXAS: 25.56 (-0.54)
MDxHealth to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum
GlobeNewswire - Wed Nov 12, 2:35AM CST
MDxHealth SA (Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that CEO, Dr. Jan Groen, will present at the Canaccord Genuity Medical Technology & Diagnostics Forum, which is being held on November 20, 2014, at Westin Grand Central in New York. Dr. Jan Groen will make the Company's presentation at 1:30 PM Eastern Daylight Time. The presentation will be posted under the investor tab of the MDxHealth website (http://mdxhealth.com/investors/shareholder-information) after the conference.
MDXHealth - Piggybacking On Exact Sciences' Cologuard Success
SNJBiostoxx - at Seeking Alpha - Thu Nov 06, 10:43AM CST
EXAS: 25.56 (-0.54)
MDxHealth Provides Third Quarter 2014 Business Update
GlobeNewswire - Tue Nov 04, 1:08AM CST
MDxHealth SA (Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today provided its third quarter Business Update for the period ended September 30, 2014.
MDxHealth's ConfirmMDx Genes Identify Prostate Cancer Aggressiveness in Diagnostic Biopsies
GlobeNewswire - Fri Oct 10, 1:11AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced positive data from an important study confirming the ability of the ConfirmMDx genes to identify prostate cancer (PCa) aggressiveness in diagnostic biopsies. The data, presented at the European Association of Urology, Section Urological Research (ESUR) meeting in Glasgow, UK (October 9-11, 2014), confirmed that the epigenetic profile of ConfirmMDx genes generated by the test is strongly correlated with established risk stratification metrics, such as Gleason Score (GS) and the NCCN (National Comprehensive Cancer Network) risk categories.
MDxHealth Presents Results from Epigenetic Test to Identify Prostate Cancer Aggressiveness at the European Association of Urology Meeting 2014
GlobeNewswire - Tue Oct 07, 1:09AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the company will present results from a validation study of an epigenetic test to predict prostate cancer (PCa) aggressiveness at the European Association of Urology, Section Urological Research meeting in Glasgow, UK (October 9-11, 2014).
MDxHealth's ConfirmMDx for Prostate Cancer Test Qualifies for Medicare Coverage Effective November 3, 2014
GlobeNewswire - Tue Sep 23, 1:19AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that its ConfirmMDx for Prostate Cancer test qualifies for Medicare coverage effective November 3, 2014.
MDxHealth to Participate in the Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Mon Sep 08, 9:33AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the company will participate in the Rodman & Renshaw 16th Annual Global Investment Conference in New York, NY.
MDxHealth Reports First Half Year 2014 Results
GlobeNewswire - Thu Aug 21, 1:12AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced results of the first-half year ended June 30, 2014.
MDxHealth ConfirmMDx Biomarker Associated with the Risk of Recurrence for Early Stage Prostate Cancer Patients
GlobeNewswire - Mon Aug 18, 1:07AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that one of the ConfirmMDx for Prostate Cancer epigenetic genes is independently associated with risk of recurrence in patients with early prostate cancer (PCa). The results from this study, published in The Journal of Urology [The Journal of Urology (2014), doi: 10.1016/j.juro.2014.04.082], suggest that epigenetic analysis could play a clinical role in identifying patients who have a slow growing cancer eligible for active surveillance from those with a higher risk of recurrence who may benefit from a more aggressive therapeutic approach.
MDxHealth Signs Two New Insurance Agreements Providing Increased Access to ConfirmMDx for Prostate Cancer
GlobeNewswire - Thu Aug 14, 1:07AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that it has signed agreements with Ancillary Care Services (ACS), a subsidiary of American CareSource Holdings Inc. and separately, Consilium, LLC. ACS offers its providers quality and cost-effective healthcare services through their managed care network agreements covering 4.5 million lives. Consilium is a complete solution provider for out-of-network healthcare claims. The agreements provide patients access to MDxHealth's ConfirmMDx for Prostate Cancer test.
ANCI: 3.10 (-0.20)
MDxHealth (R) : MDxHealth Licensee Exact Sciences Receives FDA Approval for its Cologuard Colon Cancer Screening Assay
GlobeNewswire - Tue Aug 12, 2:05AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the U.S. Food and Drug Administration's (FDA) has approved Exact Sciences' Cologuard(R) stool-DNA-based, non-invasive colorectal cancer screening test. The test incorporates one of MDxHealth's epigenetic biomarkers, which was licensed to Exact Sciences in July 2010. Upon product launch, anticipated before the end of 2014, MDxHealth expects to receive milestone payments and royalties from the sale of the test under the terms of its licensing agreement.
ConfirmMDx Studies Highlighted by Elsevier, Publisher of The Journal of Urology(r)
GlobeNewswire - Tue Jul 22, 1:08AM CDT
Underscores Importance of Recent Confirmatory Clinical Validation Results Leading to Medicare Reimbursement Milestone
MDxHealth and Miraca Life Sciences Announce Agreement to Promote ConfirmMDx for Prostate Cancer
GlobeNewswire - Wed Jul 02, 1:06AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that it has entered into an agreement with Miraca Life Sciences (MLS), the nation's largest independent anatomic pathology lab, to promote MDxHealth's ConfirmMDx for Prostate Cancer test. Serving more than 5,500 patients each day, Miraca Life Sciences is a national leader in providing academic-caliber pathology services in the fields of dermatology, hematology, gastroenterology and urology.
MDxHealth Reports Fourth Quarter and Fiscal Year 2013 Results
GlobeNewswire - Thu Feb 27, 1:05AM CST
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced results for the fourth quarter and the fiscal year ended December 31, 2013. This year the company has changed its reporting currency to U.S. Dollars, while keeping its functional currency in Euros.
BAS: 7.28 (+0.62)
